New England Research & Management Inc. Lowers Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

New England Research & Management Inc. lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 59.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 845 shares of the company's stock after selling 1,250 shares during the period. New England Research & Management Inc.'s holdings in IDEXX Laboratories were worth $355,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Everhart Financial Group Inc. lifted its position in IDEXX Laboratories by 72.3% during the first quarter. Everhart Financial Group Inc. now owns 1,285 shares of the company's stock valued at $540,000 after purchasing an additional 539 shares during the last quarter. Marshall Financial Group LLC increased its stake in shares of IDEXX Laboratories by 14.5% in the first quarter. Marshall Financial Group LLC now owns 2,286 shares of the company's stock worth $960,000 after buying an additional 290 shares during the period. Mogy Joel R Investment Counsel Inc. increased its stake in shares of IDEXX Laboratories by 8.1% in the first quarter. Mogy Joel R Investment Counsel Inc. now owns 85,724 shares of the company's stock worth $36,000,000 after buying an additional 6,400 shares during the period. Fifth Third Bancorp increased its stake in shares of IDEXX Laboratories by 102.2% in the first quarter. Fifth Third Bancorp now owns 6,075 shares of the company's stock worth $2,551,000 after buying an additional 3,071 shares during the period. Finally, Simon Quick Advisors LLC purchased a new position in IDEXX Laboratories during the 1st quarter valued at $360,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded down $4.22 on Friday, hitting $522.70. The company had a trading volume of 411,464 shares, compared to its average volume of 650,612. The company has a market capitalization of $42.04 billion, a PE ratio of 48.99, a PEG ratio of 3.41 and a beta of 1.55. The company's fifty day moving average price is $473.11 and its 200-day moving average price is $444.45. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $530.73.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. During the same quarter in the previous year, the firm earned $2.71 EPS. The firm's revenue was up 3.6% compared to the same quarter last year. As a group, analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,046 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $513.74, for a total transaction of $537,372.04. Following the sale, the director now owns 262 shares of the company's stock, valued at approximately $134,599.88. This represents a 79.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.98% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of research reports. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Stifel Nicolaus upped their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research report on Monday, May 19th. Leerink Partners increased their price objective on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research note on Wednesday. Finally, Morgan Stanley upped their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $546.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.